Charles River Laboratories International, Inc. - CRL STOCK NEWS

Charles River Laboratories (NYSE: CRL) has launched the nAAVigation Vector Platform to expedite GMP AAV vector manufacturing for gene therapy developers. This platform aims to reduce the timeline for drug production by 55%, allowing product delivery in under 8 months. The proprietary technology leverages a high-productivity HEK293 cell line and optimized processes. The platform will be introduced at the Cell & Gene Meeting on October 12 in Carlsbad, CA. This launch showcases Charles River's commitment to enhancing efficiency and speed in clinical-stage manufacturing.

Charles River Laboratories (NYSE: CRL) announced its participation in two investor conferences in New York. The Baird 2022 Global Healthcare Conference will take place on September 13 at 10:15 a.m. EDT, while the Morgan Stanley 20th Annual Global Healthcare Conference is scheduled for September 14 at 10:00 a.m. EDT. Management will provide insights into the company's strategic focus and business developments. Live webcasts will be available on the Investor Relations section of the Charles River website, with replays accessible for two weeks.

Charles River Laboratories (NYSE: CRL) has announced a collaboration with Cure AP-4 to provide high-quality plasmid DNA for Phase I/II clinical trials targeting AP-4 Hereditary Spastic Paraplegia. This partnership aims to address a rare neurodegenerative disorder caused by a genetic defect, impacting mobility and cognitive function.

With rising demand for plasmid DNA in therapeutic applications, Charles River's dedicated manufacturing center will accelerate clinical timelines. This collaboration emphasizes the company’s role in advancing innovative therapies for underserved patient populations.

Charles River Laboratories (NYSE: CRL) has expanded its Charles River Accelerator and Development Lab (CRADL) network by adding five new locations across California and Washington. This expansion follows the recent acquisition of Explora BioLabs and aims to enhance support for biopharmaceutical research. The new facilities provide flexible, turnkey vivarium rental space and access to a full suite of integrated drug discovery services. With 27 combined facilities, the network offers over 370,000 square feet of capacity in key biotech hubs globally.

Charles River Laboratories (NYSE: CRL) has received Good Manufacturing Practice (GMP) certification from the European Medicines Agency (EMA) for its Memphis CDMO facility. This approval allows the company to commercially produce allogeneic cell therapy drug products for European distribution. The certification follows a successful inspection by the Italian regulatory authority, marking Charles River as the first North American CDMO to achieve this milestone. This expands the company's capabilities in cell and gene therapy, enhancing its portfolio.

Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter 2022 revenue of $973.1 million, up 6.4% year-over-year. GAAP earnings per share (EPS) were $2.13, a 23.8% increase, while non-GAAP EPS rose to $2.77, reflecting a 6.1% increase. However, the company reduced its 2022 revenue growth guidance from 13.5%-15.5% to 9.0%-11.0% due to headwinds in the CDMO business and unfavorable foreign exchange impacts. Despite robust demand in Discovery and Safety Assessment segments, challenges from foreign currency and rising interest rates were highlighted.

Charles River Laboratories International (NYSE: CRL) is set to release its second-quarter 2022 financial results on August 3 before the market opens. A conference call will follow at 9:30 a.m. ET to discuss these results. Investors can access a live webcast of the call through the Investor Relations section of the company’s website. Charles River provides critical products and services aiding pharmaceutical and biotech companies in drug development and research.

Charles River Laboratories (NYSE: CRL) has announced the opening of its High Quality (HQ) Plasmid DNA Centre of Excellence in Cheshire, UK, aiming to enhance plasmid DNA manufacturing for cell and gene therapy development. This 16,000 square foot facility will quadruple the company’s capacity to address global supply shortages and expedite the delivery of therapeutic materials. The expansion follows the acquisition of Cognate BioServices in March 2021.

Charles River Laboratories (NYSE: CRL) and Ziphius Vaccines announced a partnership to manufacture plasmid DNA, a key component for clinical-phase research. The collaboration aims to expedite the development of Ziphius' self-amplifying RNA technology, which promises enhanced protein expression at lower doses. This deal leverages Charles River's expertise in GMP plasmid production, beneficial for Ziphius’ clinical testing and vaccine development timelines. The partnership reflects a growing focus on advanced therapies, particularly in vaccine development.